Last Updated Sep 17, 2009 12:17 PM EDT
Pfizer denies all federal, state and qui tam allegations, with two exceptions. We acknowledge certain improper actions related to the past promotion of Bextra and Zyvox. Beyond those two exceptions we deny all federal and state and qui tam claims.The suit was brought by Mark R. Westlock of Fenton, Mo., was a rep for Pfizer from 1991 to 2007, when he claims he was forced to resign. (Download Westlock v. Pfizer here.) He alleges that Dr. Neil S. Kaye of Wilmington, Del., an assistant clinical professor of psychiatry at Jefferson Medical College, received $4,000 a day in speaker fees to talk to other doctors about "the off label use of GeodonÂ® in adolescents," among other issues. He was used so frequently by Pfizer that he was flown by 'copter to some of his gigs, Westlock claims:
Some of Kaye's material was sent to Pfizer pharmaceutical sales representatives under the heading "take home selling points." The material within that package was also labelled "do not detail," ostensibly because it covered off-label material. But Westlock claims that everyone knew they were to use it in their sales pitches because the email would not have been titled "take home selling points" if they were not in fact selling points.
- Pfizer Turned NAMI Into "Trojan Horse" to Push Geodon Off-Label to Kids, Suit Claims
- "Pfizer Math" Showed Lyrica Superiority Even Though Studies Never Said That, Rep Claims
- Pfizer Rep Claims Bextra Pushed on NHL's Blue Jackets
- Pfizer Rep Claims Zoloft Touted for Failed Cheerleaders; Viagra for Women
- Pfizer Rep Alleges Viagra Promoted With Unapproved Materials: "Get Those Things Cleaned Up!"
- Pfizer Stock Shrugs Off $2.3B Bextra Fine; Can Anything Deter Off-Label Promotion?
- Pfizer Rep Describes Pushing Zyvox With Flawed Data
- Pfizer's West Side Story: How "the Sharks" Sold Bextra Off-Label
- 10 Amazing Facts About Pfizer's $2.3B Bextra Settlement